Back to mobile site

Leerink: 'CIRRUS Part D data continue to look supportive of EDG-7500’s potential'

June 16, 2026 8:55 AM EDT Send to a Friend
Leerink analyst Joseph Schwartz reiterated an Outperform rating and $50.00 price target on Edgewise Therapeutics (NASDAQ: EWTX)The analyst comments "CIRRUS ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login